1. Advances in CKD

3. Alport Syndrome Introduction

4. Alport Syndrome Genetics

5. Alport Syndrome Epidemiology

6. Alport Syndrome Renal Manifestations

7. Alport Syndrome Renal Pathology

8. Management of Alport Syndrome

9. Management of Alport Syndrome (cont)

10. miR-21 Plays a Major Role in Progressive Kidney Injury

11. miR-21

12. NF-κB is a Key Promoter of Inflammation

13. Keap1 and Nrf2 Interaction

14. The Keap1-Nrf2 Pathway Helps Resolve Inflammation

15. Bardoxolone Phase 2 and 3 Studies in Patients With Diabetic CKD

16. BEACON Safety Finding: Acute Fluid Overload in Patients With Prior History of HF or Elevated BNP in First 4 Weeks

17. TSUBAKI Study (Japan) in Patients With Diabetic CKD

18. CARDINAL Phase 2 Open-Label Study Design

19. CARDINAL Phase 2 Primary Efficacy Analysis

20. CARDINAL Phase 2 Distribution of eGFR Changes

21. Bardoxolone in CKD: Proven Effect on Measured GFR and Safety Concerns Addressed, Studies Ongoing

22. Bardoxolone in CKD: Studies Ongoing

23. miR-21 is Highly Expressed in the Kidney Prior to and During CKD Progression

24. Anti-miR-21 From Week 3 to 16 Protects Against CKD and Prolongs Survival in an Alport Model

25. Anti-miR-21 Agent for Humans RG-012

26. An Observational Study of Patients With Alport Syndrome

27. Trials of RG-012 anti-miR-21 in Patients With Alport Syndrome

28. Closing Comments

29. Abbreviations

30. Abbreviations (cont)